Clinical Registry
We use data from the BioCells Medical clinical registry, which has been collected since 2013. This is an observational study in which patients are followed over time.
Study design: Observational · Non-randomised · No placebo control
2,500+
Patients
in clinical registry
5
Clinical Areas
neurological, autoimmune, respiratory
12
Years
continuous data collection
6+mo
Follow-Up
minimum observation period
Neurological Conditions
Paediatric Neurology
Systemic Autoimmune Conditions
Respiratory Conditions
Musculoskeletal & Orthopaedic
Stabilisation rate: proportion of patients with no measurable functional decline at ≥6 months. Sorted by cohort size.
| Diagnosis | Scale | n | Stabilisation | Primary Endpoint | Response | |
|---|---|---|---|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) | ALSFRS-R | 257 | 76% | Functional score stabilisation at ≥6 months | 3–4 weeks | Protocol → |
| Multiple Sclerosis (MS) | EDSS | 288 | 79% | Disability score stabilisation, annualised relapse rate reduction | 2–3 weeks | Protocol → |
| Autism Spectrum Disorder (ASD) | CARS / ABC | 83 | 78% | Behavioural and social function improvement | 2–4 weeks | Protocol → |
| Parkinson’s Disease | UPDRS | 79 | 77% | Motor score stabilisation, tremor and rigidity reduction | 3–5 weeks | Protocol → |
| Peripheral Neuropathy | NIS / TNS | 127 | 81% | Neuropathy score improvement, pain and numbness reduction | 2–3 weeks | Protocol → |
| Alzheimer’s Disease & Dementia | MMSE / MoCA | 98 | 74% | Cognitive score stabilisation at ≥6 months | 4–6 weeks | Protocol → |
| Cerebral Palsy | GMFCS / GMFM | 70 | 73% | Motor function and coordination improvement | 3–5 weeks | Protocol → |
| Muscular Dystrophy | MRC / North Star | 45 | 75% | Muscle strength stabilisation, ambulatory function | 4–6 weeks | Protocol → |
| Multiple System Atrophy (MSA) | UMSARS | 94 | 69% | Autonomic and motor score stabilisation | 3–5 weeks | Protocol → |
Functional score stabilisation at ≥6 months
View full protocol →
Disability score stabilisation, annualised relapse rate reduction
View full protocol →
Behavioural and social function improvement
View full protocol →
Motor score stabilisation, tremor and rigidity reduction
View full protocol →
Neuropathy score improvement, pain and numbness reduction
View full protocol →
Cognitive score stabilisation at ≥6 months
View full protocol →
Motor function and coordination improvement
View full protocol →
Muscle strength stabilisation, ambulatory function
View full protocol →
Autonomic and motor score stabilisation
View full protocol →
Study Design
The study is based on observing patients: all patients enrolled in the BioCells Medical registry since 2013 are included. Patients are not assigned randomly, as is the case in classical clinical trials.
Population
Adult and paediatric patients with confirmed diagnoses across 5 clinical areas who completed at least one full treatment cycle and the minimum follow-up period (≥6 months). No exclusion by disease stage or prior treatment history.
Outcome Measures
Primary endpoint: disease stabilisation, defined as absence of measurable functional decline on the relevant validated clinical scale over the observation period. Secondary endpoints: scale-specific score improvement, patient-reported quality of life, and time to clinical response.
Instruments: Validated instruments include ALSFRS-R, EDSS, UPDRS, UMSARS, GMFCS/GMFM, CARS/ABC, MMSE/MoCA, NIS/TNS, and MRC/North Star. Scale selection follows international clinical guidelines for each diagnosis.
Limitations
Data Governance
All clinical data is maintained in an electronic registry with access restricted to authorised medical personnel. Data collection and storage comply with GDPR and Polish medical record-keeping regulations. Outcomes are reviewed quarterly by the internal medical review board.
For Referring Physicians
Our medical team is available for physician-to-physician consultations. We can provide detailed outcome data for specific diagnoses, discuss eligibility criteria, or review a patient case. All communications are confidential.
